culturing repertoire
Living repertoire · generative specimen

Reading the immune system, one clone at a time.

Kilian Maire, immunologist specialised in Th2 lymphocyte and T-cell receptor repertoire biology. Founder & CEO of Biotraxion and KIMA Holding, building at the edge of biology and AI.

node = T-cell clone edges = shared lineage size ∝ clonal abundance click to expand a clone
Fig. 01Profile

I study how the immune repertoire decides between tolerance and disease, linking clonal diversity to T-cell fate, tissue adaptation, and pathogenic potential.

As a postdoctoral researcher at the University of Copenhagen (Skin Immunology Research Center, LEO Foundation, dir. Pr. Jonathan Coquet), I investigate TCR repertoire dynamics across human and mouse models, integrating single-cell and bulk repertoire analyses with high-dimensional immunophenotyping and functional assays.

My doctoral work at INFINITY (Toulouse) uncovered filamin dosage as a control node for Th2 lymphocyte function, a mechanism now protected by a European patent and translated toward asthma therapy.

Beyond the bench, I build. As founder & CEO of Biotraxion and KIMA Holding, I drive product vision and R&D across embedded systems, computer vision and AI, taking laboratory science into regulated, real-world deployment.

Kilian Maire
Kilian Maire · Copenhagen2026
FieldImmunology Th2 · TCR repertoire
Experience10+ years at the bench
Ventures founded2 Biotraxion · KIMA Holding
Intellectual property1 European patent
Fig. 02Research

Peer-reviewed work on the molecular mechanisms tuning type-2 immunity, and the therapeutic openings they reveal.

Fig. 03Ventures

From the bench to the build, companies taking lab science into regulated practice.

biotraxion.com ↗

Biotraxion

Founder & CEO

A traceability platform for the modern lab: from scientific problem to system architecture, regulatory strategy and go-to-market. R&D across embedded systems, computer vision, AI and cloud, built for compliance and human-machine interaction in regulated environments.

Computer VisionEmbeddedAICloudTraceability

KIMA Holding

Founder & CEO

The holding behind the ventures, driving business strategy, fundraising, IP and freedom-to-operate analysis, and partnerships with academic labs, hospitals and biotech/pharma stakeholders.

StrategyIP / FTOFundraisingPartnerships
Fig. 04Open code

Multi-agent and multi-session AI probing immune repertoires and allergy multi-omics on public data, published openly.

Fig. 05Writing

Essays on immunology, AI and what it means to build science, Le Substack de Kilian.

Read all essays on Substack ↗
Fig. 06Outreach

Ma thèse en 180 secondes , my doctoral thesis, explained to a general audience in three minutes.

Fig. 07Connect
Open to collaboration

Let's read the repertoire together.